Home Duke University Press
QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

First published on May 15, 2007
This version was published on July 1, 2007
Neuro Oncol 2007 9(3):291-297; DOI:10.1215/15228517-2007-009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
9/3/291    most recent
15228517-2007-009v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holtkamp, N.
Right arrow Articles by von Deimling, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Duke University Press

Basic and Translational Investigations

Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme

Nikola Holtkamp, Nicolas Ziegenhagen, Elke Malzer, Christian Hartmann, Alf Giese and Andreas von Deimling

Institute of Neuropathology, Charité-Universitätsmedizin Berlin, 13353 Berlin (N.H., N.Z., E.M., C.H.); Department of Neurosurgery, Georg-August-Universität, 37073 Göttingen (A.G.); Department of Neuropathology, Ruprecht-Karls-Universität, 69120 Heidelberg (A.v.D.); Germany

Address correspondence to Andreas von Deimling, Department of Neuropathology, Ruprecht-Karls-Universität, Im Neuenheimer Feld 220, 69120 Heidelberg, Germany (andreas.vonDeimling{at}med.uni-heidelberg.de).

A subset of glioblastomas (GBMs) carry gene amplifications on chromosomal segment 4q12. To characterize this amplicon in detail, we analyzed a set of 100 samples consisting of 65 GBMs, 10 WHO grade III astrocytomas, 12 oligodendrogliomas, and 13 glioma cell cultures. We applied multiplex ligation-dependent probe amplification to determine the gene dosage of PDGFRA, KIT, and KDR and the flanking genes USP46, RASL11B, LNX1, CHIC2, SEC3L1, and IGFBP7. The amplicon was highly variable in size and copy number and extended over a region of up to 5 Mb. Amplifications on 4q12 were observed in 15% of GBMs and 23% of GBM cell cultures but not in 22 other gliomas. We analyzed transcription and translation of some genes within this amplicon. Gene amplification generally correlated with high transcript levels but did not necessarily result in increased protein levels. However, we detected frequent expression of proteins encoded by PDGFRA, KIT, and KDR in GBMs and GBM cell cultures independent of the amplification status. Future treatment of GBM patients may include drugs targeting multiple kinases that are encoded by genes on chromosomal segment 4q12.

Key Words: gene amplification • glioblastoma • KDR • KIT • PDGFRA






  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents


Copyright 2007 by Society for Neuro-Oncology